First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies.

Jordan D BerlinAnthony W TolcherCliff DingJennifer G WhisenantIvan D HorakDebra L WoodPaul I NadlerUlla Holm HansenJohan LanttoNiels Jørgen Ø SkartvedMikkel W PedersenAmita Patnaik

Published in: Investigational new drugs (2022)

gov ; NCT02906670 (September 20, 2016).

Keyphrases

endothelial cells
study protocol
phase iii
induced pluripotent stem cells
phase ii
randomized controlled trial
open label